Objective: To determine whether 17-a hydroxyprogesterone (17-OHPC) alters tumor necrosis factor-a (TNF-a) production and the expression of cyclooxygenase type 2 (COX-2) in myometrium exposed to lipopolysaccharide (LPS).
Introduction
Preterm birth is a leading cause of neonatal morbidity and mortality in developed countries. 1 Despite efforts to reduce preterm birth through the use of tocolytics, cerclage and bed rest, the rate of preterm birth in the United States increased from 9 to 12% over the past two decades.
Prostaglandins have a critical role in the labor process. Prostaglandins (for example, prostaglandin E 2 and prostaglandin F 2a ) are responsible for physical alterations that lead to changes such as cervical softening, priming of oxytocin receptors and increasing gap junctions. These changes eventually lead to regular uterine contractions and cervical dilation. Moreover, the production of prostaglandins is mediated in part by the enzyme, cyclooxygenase-2 (COX-2). An increase in COX-2 results in an increase in the production of prostaglandins. The role of COX-2 in parturition has been shown in studies as an increase in its expression with advancing gestational age and before the onset of labor. 2 In addition, physiologic studies have shown that myometrial cell stretch leads to increased COX-2 mRNA and COX-2 protein levels. 3 One major cause of preterm birth is infection. 4, 5 Clinically apparent intrauterine infection, also known as chorioamnionitis, has been shown to be present in the setting of preterm labor with intact membranes and in 30% of cases of preterm premature rupture of membranes. It has also been implicated in 50% of very low birth weight infants born before 30 weeks of gestation. 4 However, both subclinical infection, which is observed only on histopathology, and sterile inflammatory processes have also been associated with labor. 6 In all these situations, the release of cytokines have been linked with the initiation of the labor process. Many studies have analyzed the pregnancy-specific role of cytokines such as interleukin-6 (IL-6), IL-8 and tumor necrosis factor-a (TNF-a). [6] [7] [8] [9] Although the literature shows conflicting data regarding the changes to IL-6, IL-8 and TNF-a, most studies show that they are increased in the setting of term labor and preterm labor. TNF-a has been shown to be elevated in term labor and implicated in preterm labor. Amniotic fluid samples from patients with spontaneous labor at term compared with those undergoing elective cesarean section show that IL-6 and IL-8 concentrations increase, and TNF-a levels increase to a detectable level. 6 In a primate model, TNF-a induced preterm labor when injected into the amniotic cavity. 10 It has also been shown that maternal serum TNF-a and mRNA expression of placental TNF-a are higher in preterm labor complicated by chorioamnionitis when compared with preterm labor without chorioamnionitis. 11 These increases in TNF-a in turn have been shown to increase COX-2 production and subsequent prostaglandin synthesis. 12 Meis et al. 13 studied the effect of 17-a hydroxyprogesterone caproate (17-OHPC) therapy in the prevention of preterm birth in women with a history of previous preterm birth. A significant reduction in the rate of recurrent preterm birth was shown with the administration of weekly injections of 17-OHPC. Despite this clinical benefit, the mechanism by which 17-OHPC works is limited at best. Facchinetti et al.
14 showed that 17-OHPC inhibits IL-1b secretion in the cervix but there was no change in cervical secretions of IL-6, IL-8 and TNF-a.
There are many infectious agents associated with intrauterine infection. Gram-negative organisms linked with preterm birth include Neisseria gonorrhoeae, bacteroides species and Escherichia coli. Lipopolysaccharide (LPS), a component of the cell wall of Gramnegative bacteria, has been shown to induce COX-2 production. 15 The purpose of this pilot study was to analyze whether or not 17-OHPC had an effect on altering human myometrial production of TNF-a and COX-2 mRNA and protein after exposure to LPS.
Methods

Tissue collection
This study was approved by the institutional review board of the Los Angeles County-University of Southern California Medical Center. Informed consent was obtained from all patients before tissue collection.
All patients were carrying term, singleton pregnancies and undergoing elective cesarean delivery. Exclusion criteria for enrollment included: labor, history of preterm birth, treatment with any form of progesterone during the pregnancy and any condition that might have led to excessive bleeding after biopsy. After delivery of the fetus, myometrium (2 Â 2 cm) was trimmed from the upper aspect of the lower uterine segment. The myometrium was carefully dissected and trimmed of any decidua to avoid heterogeneous tissue sampling. A portion of the tissue specimen was immediately frozen on dry ice and stored at -70 1C for total RNA isolation. Another portion was fixed in 10% buffered formalin for paraffin block and routine histological evaluation and immunohistochemistry.
Explants culture and treatments Explant cultures were prepared from 10 myometrial biopsies. Myometrial tissues were immediately transferred to the laboratory after delivery. Portions of each sample were frozen and fixed in 10% buffered formalin for subsequent baseline measurements. Remaining specimens were rinsed with Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) complemented with 1% antibiotic and antimycotic solution (containing 100 U/ml penicillin, 100 mg/ml streptomycin and 250 ng/ml amphotericin B; GIBCO, Carlsbad, CA, USA), placed in a 100-mm plastic tissue culture dish (uncoated; BD Biosciences, San Jose, CA, USA) and cut with sterile scalpels into 10 to 15 mg pieces. For one incubation, 8 to 10 pieces were combined and placed into one well of a 12-well plate containing 1.5 ml of culture medium. After pre-incubation for 60 min in a humidified atmosphere of 95% O 2 and 5% CO 2 at 37 1C, in addition to the control vehicle, explants were incubated with LPS alone (1 mg/ml; Sigma-Aldrich, St Louis, MO, USA), 17-OHPC alone (1 mM; Adeza Biomedical Corporation, Sunnyvale, CA, USA) or in a combination of LPS and 17-OHPC in serum-free media for 24 h. Tissue viability and responsiveness was checked at the end of the incubation period. Pieces of explants, three to four in number, were quick-frozen and stored at À70 1C for total RNA isolation and the rest of the explants were fixed in a 10% buffered formalin for paraffin block and immunohistochemistry study.
Because 17-OHPC is a lipid-soluble compound, it was necessary to dissolve it in a lipophilic vehicle. The vehicle used in this study was ethanol, and a 1 mmol/l (1 mM) stock solution of 17-OHPC was made. Fresh 17-OHPC solutions were prepared on the day of experimentation. On the basis of an in vitro study analyzing the effect of 17-OHPC on human myometrial contractility, we analyzed the dynamics of treatment with 17-OHPC alone, and performed dose-response (10 nM, 100 nM, 1 mM and 10 mM) and time-response analyses (2, 6, 12 and 24 h) of COX-2 mRNA expression. 16 No significant dose-and time-dependent change in COX-2 mRNA expression was found (data not shown). Because of this and the fact that in vitro studies analyzing progesterone in myometrium have used the same concentration, 17-OHPC at a concentration of 1 mM was used for the remaining experiments.
17,18 LPS at 0.1, 1 and 10 mg/ml was also tested and optimized, and 1 mg/ml was used to induce inflammation for all experiments based on our previous studies. 19 Enzyme-linked immunosorbent assay TNF-a production was measured using enzyme-linked immunosorbent assay (human TNF-a Quantikine ELISA kit, R&D Systems, Minneapolis, MN, USA) according to the manufacturer's specifications. Frozen culture supernatant samples were thawed on ice and diluted 1:10 in diluents provided by the manufacturer. TNF-a concentrations were estimated by interpolation from the Effect of 17-OHPC on human myometrium S Patel et al calibration curve obtained using TNF-a standard. Mean intra-assay coefficient of variance was from 3.5 to 7.1%, and the minimum detectable dose of TNF-a ranged from 0.5 to 5.5 pg/ml.
Real-time PCR (RT-PCR)
Relative amounts of COX-2 mRNA in the human myometrium samples were assessed using RT-PCR as described previously. [20] [21] [22] [23] In brief, total RNA from baseline or cultured myometrial samples was extracted using TRIzol Reagent (Invitrogen). A total of 2 mg of total RNA were reverse transcribed with SuperScript II First-Strand Synthesis System for RT-PCR (Invitrogen), according to the manufacturer's instructions. The quantification of COX-2 mRNA was performed using a LightCycler (Roche, Mannheim, Germany). Oligonucleotide primers were designed using LightCycler Probe Design software. The nucleotide sequences of the primers used and resultant PCR product sizes were: (1) human COX-2: forward: 5 0 -CTTCACGCATCAGTTTTTCAAG-3 0 and reverse: 5 0 -TCACCGTAAAT ATGATTTAAGTCCAC-3 0 (96 bp); and (2) glyceraldehyde-3-phosphate dehydrogenase: forward: 5 0 -CTTCCCCTCCATCGTGGG-3 0 and reverse: 5 0 -GTGGTACGGCCAGAGGCG-3 0 (225 bp). The assay for each sample was performed in duplicate. In addition, the amplicons were checked using agarose gel electrophoresis for a single band of the expected size.
Relative quantification analysis was carried out using LightCycler software, version 4 (Roche). The results were expressed as a normalized ratio. Comparison was made between the ratio of COX-2 to glyceraldehyde-3-phosphate dehydrogenase in samples from treated explants, to the ratio of the same two genes in samples from vehicle-treated controls, which served as a 'Calibrator' (1 Â sample).
Immunohistochemistry
Routinely prepared paraffin sections (5 mm) were used to analyze the distribution of COX-2 as described previously with some modifications. 19 In brief, sections were deparaffinized and boiled in microwave in 10 Mm citrate buffer, pH 6.0 (Zymed Laboratories, South San Francisco, CA, USA) for 8 min.
Endogenous peroxidase activity was quenched using 3% hydrogen peroxide. After normal serum blocking, the sections were incubated with anti-human COX-2 mouse monoclonal antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 1C for overnight. Impress anti-mouse immunoglobulin G was applied for 50 min at room temperature. Staining was visualized using peroxidase substrate kit DAB (Vector Laboratories, Burlingame, CA, USA). Counterstaining was performed lightly with hematoxylin. The sections were then dehydrated and coverslipped. Examination and photography were performed using an Olympus BX-50 light microscope equipped with a Canon EOS D30 digital camera (Tokyo, Japan). The following negative controls were carried out to verify specificity of the immunoreactivity. Primary antibody was substituted by antibody dilution buffer or non-immune mouse serum (1:1000; Vector Laboratories).
Semiquantification of immunoreactivity for the expression of COX-2 was performed in each sample by evaluating the percentage of stained cells and staining intensity. The proportion of stained cells was graded as 0, 1, 2 or 3 (positive staining signal in 0, <10, 10 to 50 or >50 of cells, respectively). The intensity of staining was graded as: 1 (weak), 2 (moderate) or 3 (strong). The staining index was calculated according to the following equation: percentage of stained cells multiplied by the staining intensity, allowing for a minimum score of 0 and a maximum score of 9. 24 The average of the scores of two independent, blinded observers was calculated and taken as the staining index. All samples were evaluated at a Â 400 magnification.
Statistical analysis
Statistical analysis was performed using SPSS, Version 17.0 (SPSS, Chicago, IL, USA) and Excel 2002 (Microsoft, Redmond, WA, USA). Paired non-parametric tests were used to compare control and inflammatory mediator-treated explants samples. The data were expressed as median and interquartile range. Differences were considered significant at a level of P<0.05. No sample size calculations were performed as this was a pilot study.
Results
In all, 10 patients were enrolled. The median age of the patients was 33.0 years (25.75 to 35.75), the median gravity was 3.0 (3.0 to 4.75) and the median parity was 2.0 (2.0 to 2.75). The median gestational age was 39.0 weeks (38.93 to 39.44).
TNF-a production
As shown in Table 1 , 17-OHPC alone had no significant effect on the production of TNF-a in comparison to the control group (0.61 pg/ml (0.18 to 1.08) vs 1.0 pg/ml (1.0 to 1.0), P ¼ 0.61). However, the tissues treated with LPS alone showed a significant increase in the concentration of TNF-a when compared with the control group (304.0 pg/ml (144.0 to 931.0) vs 1 pg/ml (1.0 to 1.0), P ¼ 0.03). Explants treated with both 17-OHPC and LPS showed no significant difference when compared with the LPS-only group (357.0 pg/ml (168.5 to 653.5) vs 304.0 pg/ml (144.0 to 931.0), P ¼ 0.37). The results indicate that in our myometrial explants model, LPS induced a dramatic inflammatory response and 17-OHPC treatment did not alter the inflammatory reaction.
COX-2 mRNA expression RT-PCR was performed to measure the relative amounts of COX-2 mRNA in response to different treatments. Tissue samples treated with 17-OHPC alone did not have a difference in COX-2 mRNA expression compared with the control group (P ¼ 0.95). In contrast, tissues treated with LPS alone showed a 5.8-fold increase (2.6 to 11.1) in the expression of COX-2 mRNA when compared with the control group (P ¼ 0.02). In addition, when the explants were treated with both 17-OHPC and LPS, there was no significant difference in the expression of COX-2 mRNA when compared with samples treated with LPS only (11.6 (4.3 to 18.9) vs 5.8 (2.6 to 11.1), P ¼ 0.12; Table 1 ).
COX-2 immunoreactivity
To verify the above mRNA results, immunohistochemical staining for COX-2 protein was performed (Table 1) . COX-2 protein could be detected by immunohistochemistry in human myometrium before and after treatment. The immunoreactivity of COX-2 was predominantly localized in the cytoplasm of myocytes in both longitudinal and circular muscle layers. The control group had a staining index of 6.0 (2.7 to 7.9). The group treated with 17-OHPC alone had a staining index of 9.0 (4.8 to 9.0) and was not significantly different from the control group (P ¼ 0.1). The explants treated with LPS alone had a staining index of 9.0 (6.6 to 9.0), which was not different from the control group (P ¼ 0.1). The staining index of the 17-OHPC-and LPS-treated group was 9.0 (5.8 to 9.0), which was not different from the LPS-only group (P ¼ 1.0).
Discussion
In our model, we found that in the setting of LPS stimulation, 17-OHPC does not alter TNF-a production or COX-2 expression from cultured human myometrial explants.
Despite the clinical efficacy of 17-OHPC in reducing recurrent preterm birth, little is currently known on its mechanism of action at the level of the human myometrium. Two experiments have failed to show 17-OHPC having an effect as an oxytocin antagonist or as an in-vitro tocolytic. 16, 25 There seems to be mounting evidence that 17-OHPC may have a role as an anti-inflammatory mediator. Facchinetti et al.
14 showed that 17-OHPC may inhibit the secretion of the proinflammatory cytokine, IL-1b, from the cervix. They further showed that in patients receiving 17-OHPC there was reduced cervical shortening. 14 Keiser et al. 26 showed in a rat model that 17-OHPC attenuated the effect of TNF-a-induced hypertension by reducing the production of endothelin. Veillon et al. 27 showed normalization of TNF-a and IL-6 in response to placental ischemia with the administration of 17-OHPC to rats. Conversely, 17-OHPC was found to have a proinflammatory effect on TNF-a production in non-pregnant human peripheral blood monocytes. 28 Having said this, the primary strength of our study is that it is the first study to our knowledge to analyze the human myometrium and the effect of 17-OHPC in an inflammatory model. A Pubmed search using the search terms '17-a hydroxyprogesterone caproate, human, myometrium, inflammation' between 1 January 1980 and 30 December 2009, in the English language failed to retrieve any studies.
We acknowledge that our study has a number of major limitations. Foremost is our small sample size. Post hoc power analysis revealed that a total of 46 myometrial samples (23 in each group) are required to achieve 80% power with an a of 0.05 to detect a significant difference in the effect of 17-OHPC on COX-2 mRNA expression from LPS-stimulated myometrium. For TNF-a, 11 626 samples would be needed for each group. Second, our decision to study myometrium biopsied from patients at term limits the ability to understand the effect of 17-OHPC in the patient for whom the medication is intendedFthe patient who delivers preterm. We found consenting patients to obtain myometrial samples difficult in an already high-risk situation; we also felt that there were a number of clinical confounders that might affect the results (for example, chorioamnionitis, preterm premature rupture of membranes, use of tocolytics and corticosteroids). Therefore, we decided to use myometrium from otherwise healthy subjects undergoing elective cesarean birth. Third, the methodology of simultaneously adding 17-OHPC in conjunction with LPS to the myometrial explants may not mimic the clinical setting in which a patient receives 17-OHPC before the onset of infection-mediated preterm birth. Perhaps a more viable model would be pretreatment of myometrium with 17-OHPC and then later adding an inflammatory agent. However, it is of interest that in our study the combined effect of adding 17-OHPC and LPS together to the myometrial explants caused an apparent increase in COX-2 mRNA expression, although not statistically significant. Next, our decision to use 17-OHPC at the concentration used was extrapolated from studies using progesterone. This assumes that 17-OHPC has a Effect of 17-OHPC on human myometrium S Patel et al direct effect on myometrial tissue at the same concentration as progesterone and, in a sense, naively dismisses the possibility that a metabolite of 17-OHPC may be entirely responsible for the reduction in recurrent preterm birth observed in clinical trials. In fact, 17-OHPC does not seem to be converted to progesterone, bind the progesterone receptor with any greater affinity than progesterone, augment progesterone or glucocorticoid gene expression response or alter the concentrations of progesterone in humans receiving 17-OHPC during pregnancy. [29] [30] [31] It is hypothesized that the effect on preterm birth may possibly be due to the caproate moiety of 17-OHPC that may alter gene silencing and thus progesterone signaling pathways. 31, 32 Given the multifactorial causes of preterm birth, elucidating the mechanism by which 17-OHPC reduces the risk for recurrent preterm birth will continue to be challenging. [33] [34] [35] [36] [37] Although the American Congress of Obstetrics and Gynecology recommends the use of progesterone in women with a previous history of spontaneous preterm birth, there are still many unknowns regarding the mechanism of actions of the progesterone agents prescribed for women with a history of preterm birth. 38 Future research is needed to understand how these agents alter physiological processes to produce clinical effects.
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